AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of “Moderate Buy” by Analysts

AstraZeneca PLC (LON:AZN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is £153.33.

AZN has been the topic of a number of analyst reports. Citigroup raised their target price on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a £115 price target on shares of AstraZeneca in a report on Friday, June 26th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a £180 price objective on shares of AstraZeneca in a report on Friday, June 26th.

Get AstraZeneca alerts:

Get Our Latest Analysis on AZN

AstraZeneca Trading Down 0.9%

Shares of AstraZeneca stock opened at £144.06 on Friday. The firm has a 50-day simple moving average of £137.37 and a two-hundred day simple moving average of £141.36. The company has a market cap of £223.42 billion, a P/E ratio of 21.70, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. AstraZeneca has a fifty-two week low of £101.22 and a fifty-two week high of £157.32. The company has a debt-to-equity ratio of 71.66, a quick ratio of 0.59 and a current ratio of 0.91.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Articles

• Five stocks we like better than AstraZeneca
• Shorting the Grid: Bloom Energy’s $25B AI Power Play
• SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
• Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
• 3 Dividend ETFs Built for Stability in a Volatile Market

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.